Cambrex (NYSE:CBM) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “

Separately, Craig Hallum reissued a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $62.33.

Cambrex (NYSE:CBM) opened at $53.00 on Monday. The company has a market capitalization of $1,692.96, a PE ratio of 17.67, a P/E/G ratio of 1.25 and a beta of 2.27. Cambrex has a 1-year low of $42.55 and a 1-year high of $62.95.

Cambrex (NYSE:CBM) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. The firm had revenue of $112.60 million during the quarter, compared to the consensus estimate of $108.44 million. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. Cambrex’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.47 earnings per share. analysts anticipate that Cambrex will post 2.97 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in CBM. Boston Partners bought a new position in Cambrex during the 3rd quarter worth approximately $17,869,000. FMR LLC lifted its holdings in Cambrex by 19.1% during the 2nd quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock worth $63,971,000 after buying an additional 171,559 shares during the last quarter. Brown Advisory Inc. lifted its holdings in Cambrex by 1,638.7% during the 3rd quarter. Brown Advisory Inc. now owns 161,577 shares of the biotechnology company’s stock worth $8,888,000 after buying an additional 152,284 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Cambrex by 117.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock worth $12,721,000 after buying an additional 125,062 shares during the last quarter. Finally, Summit Creek Advisors LLC bought a new position in Cambrex during the 4th quarter worth approximately $5,182,000.

TRADEMARK VIOLATION WARNING: “Cambrex (CBM) Raised to Hold at Zacks Investment Research” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with's FREE daily email newsletter.